Rocket PharmaceuticalsRCKT +9.25%30 PB Ratio is 1.76 as of Jul. 04, 2026. GuruFocus rates RCKT with a GF Score™ of 30/100. The stock has 3 warning signs investors should review. Among 1,228 Biotechnology companies, Rocket Pharmaceuticals ranks better than 67.75% on this metric.
The historical rank and industry rank for Rocket Pharmaceuticals's PB Ratio or its related term are showing as below:
RCKT'
s PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 1.76
Current: 1.76
During the past 13 years, Rocket Pharmaceuticals's highest PB Ratio was 1.76. The lowest was 0.00. And the median was 0.00.
RCKT's PB Ratio is ranked better than 67.75% of 1228
companies
in the Biotechnology industry
Industry Median: 2.97
vs RCKT: 1.76
During the past 12 months, Rocket Pharmaceuticals's average Book Value Per Share Growth Rate was -41.20% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -25.50% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -19.10% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -11.00% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Rocket Pharmaceuticals was 18.00% per year. The lowest was -36.10% per year. And the median was -13.90% per year.
Back to Basics: PB Ratio
Rocket Pharmaceuticals (NAS:RCKT) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Rocket Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rocket Pharmaceuticals PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Rocket Pharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where Rocket Pharmaceuticals's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Rocket Pharmaceuticals (RCKT) has a PB Ratio of 1.76 as of Jul. 04, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Rocket Pharmaceuticals and its competitors. According to the industry distribution chart, Rocket Pharmaceuticals ranks #396 out of 1228 companies in the Biotechnology industry, placing it in the top 32.2%.
Is Rocket Pharmaceuticals' PB Ratio too high?
Rocket Pharmaceuticals' current PB Ratio is 1.76. The Biotechnology industry median PB Ratio is 2.97. Rocket Pharmaceuticals' value of 1.76 is 40.7% below this industry median. Based on the distribution chart, Rocket Pharmaceuticals ranks #396 out of 1228 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Rocket Pharmaceuticals has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Rocket Pharmaceuticals' PB Ratio compare to TENX and DMAC?
According to the Biotechnology industry distribution chart, Rocket Pharmaceuticals ranks #396 out of 1228 companies for PB Ratio. This puts Rocket Pharmaceuticals in the upper half of its industry. The industry median PB Ratio is 2.97. Rocket Pharmaceuticals' value of 1.76 is 40.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.97, based on 1,228 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rocket Pharmaceuticals's current PB Ratio of 1.76 is 40.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Rocket Pharmaceuticals and its competitors. For the Biotechnology industry, the median PB Ratio is 2.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rocket Pharmaceuticals's current PB Ratio is 1.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rocket Pharmaceuticals stock overvalued right now?
Rocket Pharmaceuticals (RCKT) has a current PB Ratio of 1.76. The current PB Ratio is 1.76 and 40.7% below the Biotechnology industry median of 2.97. Rocket Pharmaceuticals' overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Rocket Pharmaceuticals (RCKT), the current PB Ratio is 1.76 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
30GF Score
Get the complete analysis for RCKT
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RCKT has been successfully added to your 
